[Current status and prospects of immunotherapy for castration-resistant prostate cancer]

Junji Yatsuda, Masatoshi Eto

Research output: Contribution to journalArticle

Abstract

Surgery, radiation and chemotherapy are three major therapies for cancer. But now, hope is being gathered in immunotherapy as a treatment for fourth. Immunotherapy has been done than before, but they are non-specific immunotherapy. Those that have become hot topics are specific immunotherapies targeting certain molecules or antigens. In this chapter, current status and prospects of immunotherapy for castration-resistant prostate cancer (CRPC) are described. As concrete examples, Sipuleucel-T(Provenge), GVAX, PROSTVAC-VF, Ipilimumab (anti-CTLA-4 mAb), anti-PD-1 mAb and anti-PSMA mAb are cited. As a result, it is not obtained results which therapy also satisfactory at present. Because of its uncertainties we are in the developmental stages of this therapy and improved outcomes might be achievable.

Original languageEnglish
Pages (from-to)2174-2178
Number of pages5
JournalNihon rinsho. Japanese journal of clinical medicine
Volume72
Issue number12
Publication statusPublished - Dec 1 2014

Fingerprint

Castration
Immunotherapy
Prostatic Neoplasms
Therapeutics
Uncertainty
Radiation
Antigens
Drug Therapy
Neoplasms
sipuleucel-T

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

[Current status and prospects of immunotherapy for castration-resistant prostate cancer]. / Yatsuda, Junji; Eto, Masatoshi.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 72, No. 12, 01.12.2014, p. 2174-2178.

Research output: Contribution to journalArticle

@article{41774fe1f1b3414a9572cbb60e5b277b,
title = "[Current status and prospects of immunotherapy for castration-resistant prostate cancer]",
abstract = "Surgery, radiation and chemotherapy are three major therapies for cancer. But now, hope is being gathered in immunotherapy as a treatment for fourth. Immunotherapy has been done than before, but they are non-specific immunotherapy. Those that have become hot topics are specific immunotherapies targeting certain molecules or antigens. In this chapter, current status and prospects of immunotherapy for castration-resistant prostate cancer (CRPC) are described. As concrete examples, Sipuleucel-T(Provenge), GVAX, PROSTVAC-VF, Ipilimumab (anti-CTLA-4 mAb), anti-PD-1 mAb and anti-PSMA mAb are cited. As a result, it is not obtained results which therapy also satisfactory at present. Because of its uncertainties we are in the developmental stages of this therapy and improved outcomes might be achievable.",
author = "Junji Yatsuda and Masatoshi Eto",
year = "2014",
month = "12",
day = "1",
language = "English",
volume = "72",
pages = "2174--2178",
journal = "Astrophysical Journal",
issn = "0004-637X",
publisher = "IOP Publishing Ltd.",
number = "12",

}

TY - JOUR

T1 - [Current status and prospects of immunotherapy for castration-resistant prostate cancer]

AU - Yatsuda, Junji

AU - Eto, Masatoshi

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Surgery, radiation and chemotherapy are three major therapies for cancer. But now, hope is being gathered in immunotherapy as a treatment for fourth. Immunotherapy has been done than before, but they are non-specific immunotherapy. Those that have become hot topics are specific immunotherapies targeting certain molecules or antigens. In this chapter, current status and prospects of immunotherapy for castration-resistant prostate cancer (CRPC) are described. As concrete examples, Sipuleucel-T(Provenge), GVAX, PROSTVAC-VF, Ipilimumab (anti-CTLA-4 mAb), anti-PD-1 mAb and anti-PSMA mAb are cited. As a result, it is not obtained results which therapy also satisfactory at present. Because of its uncertainties we are in the developmental stages of this therapy and improved outcomes might be achievable.

AB - Surgery, radiation and chemotherapy are three major therapies for cancer. But now, hope is being gathered in immunotherapy as a treatment for fourth. Immunotherapy has been done than before, but they are non-specific immunotherapy. Those that have become hot topics are specific immunotherapies targeting certain molecules or antigens. In this chapter, current status and prospects of immunotherapy for castration-resistant prostate cancer (CRPC) are described. As concrete examples, Sipuleucel-T(Provenge), GVAX, PROSTVAC-VF, Ipilimumab (anti-CTLA-4 mAb), anti-PD-1 mAb and anti-PSMA mAb are cited. As a result, it is not obtained results which therapy also satisfactory at present. Because of its uncertainties we are in the developmental stages of this therapy and improved outcomes might be achievable.

UR - http://www.scopus.com/inward/record.url?scp=84922219742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922219742&partnerID=8YFLogxK

M3 - Article

C2 - 25518354

AN - SCOPUS:84922219742

VL - 72

SP - 2174

EP - 2178

JO - Astrophysical Journal

JF - Astrophysical Journal

SN - 0004-637X

IS - 12

ER -